| Similar Articles |
|---|
 |
The Motley Fool
April 27, 2006
Brian Gorman |
PAREXEL Can Do Better Despite heartening recent results, the drug research company's profitability could be better. These shares aren't terribly cheap and it appears that investors' expectations are running high.   |
The Motley Fool
August 11, 2006
Brian Gorman |
PAREXEL Takes It Up a Notch The company reported higher profitability in the fourth quarter, and management expects the trend to continue. Investors, is this worth a closer look? |
The Motley Fool
October 24, 2005
Brian Gorman |
PAREXEL Gets Squeezed First-quarter results reflect tough competition in the contract research industry. For now, this may be one stock to avoid. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
Pharmaceutical Executive
October 1, 2011 |
The Enterprising CRO Josef von Rickenbach, President & CEO of Parexel continues to lead the company, which has morphed from functional service provider to full-service global organization. |
The Motley Fool
March 20, 2006
Brian Gorman |
Much Ado About PAREXEL The contract research services provider's shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense. Investors, take note. |
The Motley Fool
June 10, 2005
Brian Gorman |
PAREXEL's New Risk The contract pharmaceutical research services provider is realigning its business, but even with reduced U.S. operations, it faces increased risk. Investors, beware. |
The Motley Fool
July 29, 2005
Stephen Ellis |
eResearch Misses a Beat Is eResearch Technology a dirt-cheap company or value trap? There are good reasons to suggest that the provider of ECG collection and interpretation services to the pharmaceutical industry does not deserve the shellacking that it has been receiving over the past year. |
The Motley Fool
January 27, 2011
Seth Jayson |
Here's How Pharmaceutical Product Development May Be Failing You Here's the current margin snapshot for Pharmaceutical Product Development and some of its sector and industry peers and direct competitors. |
The Motley Fool
July 22, 2009
Robert Steyer |
Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry. |
The Motley Fool
April 28, 2006
Brian Gorman |
Kendle Stays Hot The small contract research outfit seems like a safe bet in the near term, but investors should closely monitor the firm's performance. |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
Bio-IT World
August 2005
Ellen H. Julian |
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. |
The Motley Fool
February 14, 2006
Brian Gorman |
Kendle's on Solid Ground The contract research services outfit is on track for another good year. Investors, take note. |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life. |
